Boehringer Ingelheim Partners with Cigna's Quallent to Expand Access to Humira Biosimilar

Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer's biosimilar to Humira (adalimumab), in the US.

Under the terms of the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent. Boehringer Ingelheim will continue to commercialize company-labeled Cyltezo (adalimumab-adbm) injection and adalimumab-adbm.

Quallent will be offering both high-concentration (40 mg/0.4 mL) and low-concentration (40 mg/0.8 mL) citrate-free formulations of adalimumab-adbm as a pre-filled syringe or pen. Adalimumab-adbm's interchangeability designation for the low-concentration formulation will extend to Quallent's 40 mg/0.8 mL private-labeled adalimumab-adbm.